USD 0.59
(-4.76%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 1.26 Million USD | 134.75% |
2022 | 540.43 Thousand USD | -50.87% |
2021 | 1.09 Million USD | 354.91% |
2020 | 241.79 Thousand USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | - USD | -100.0% |
2024 Q2 | 1.58 Million USD | 0.0% |
2023 FY | 1.26 Million USD | 134.75% |
2023 Q2 | 983.36 Thousand USD | 33.07% |
2023 Q1 | 738.98 Thousand USD | 36.74% |
2023 Q3 | 1.19 Million USD | 21.94% |
2023 Q4 | 1.26 Million USD | 5.8% |
2022 Q4 | 540.43 Thousand USD | 35.85% |
2022 Q3 | 397.81 Thousand USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
AIM ImmunoTech Inc. | 495 Thousand USD | -156.3% |
Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -363.024% |
Armata Pharmaceuticals, Inc. | 120.37 Million USD | 98.946% |
Actinium Pharmaceuticals, Inc. | 2.11 Million USD | 39.958% |
Azitra, Inc. | 885.94 Thousand USD | -43.201% |
Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -3071.792% |
Calidi Biotherapeutics, Inc. | 7.23 Million USD | 82.467% |
CEL-SCI Corporation | 13.57 Million USD | 90.652% |
iBio, Inc. | 4.46 Million USD | 71.554% |
Lineage Cell Therapeutics, Inc. | 2.95 Million USD | 57.023% |
MAIA Biotechnology, Inc. | - USD | -Infinity% |
Matinas BioPharma Holdings, Inc. | 3.55 Million USD | 64.323% |
Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | 47.883% |
NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | 53.698% |
NanoViricides, Inc. | - USD | -Infinity% |
Oragenics, Inc. | 312.7 Thousand USD | -305.716% |
BiomX Inc. | 15.09 Million USD | 91.594% |
BiomX Inc. | 15.09 Million USD | 91.594% |
Protalix BioTherapeutics, Inc. | 26.28 Million USD | 95.173% |
Palatin Technologies, Inc. | 590.33 Thousand USD | -114.908% |
Scorpius Holdings, Inc. | 14.04 Million USD | 90.965% |